New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
13:57 EDTCELGCelgene announced updated OS results from post-hoc analysis of Abraxane study
Celgene announced updated Overall Survival, OS, results from a post-hoc analysis of its phase III IMPACT, Metastatic Pancreatic Adenocarcinoma Clinical Trial, study of ABRAXANE, paclitaxel protein-bound particles for injectable suspension, in combination with gemcitabine in treatment-na´ve patients with metastatic pancreatic cancer. A poster discussion of the analysis is scheduled for Sunday, June 1st at 11:30 am CT at the 50th American Society of Clinical Oncology, ASCO, annual meeting in Chicago, Ill. The analysis also showed that the treatment effect on OS for pre-specified subgroups analyzed in the trial remained consistent across patient subgroups. Specifically, patients with Karnofsky Performance Status, KPS, KPS 90-100 had a higher median OS on ABRAXANE plus gemcitabine as compared to gemcitabine alone [median OS 9.7 months vs. 7.9 months. Patients with KPS 70-80 also maintained a benefit [median OS 7.6 months vs. 4.3 months. This updated analysis also evaluated the prognostic effects of CA19-9 and neutrophil-to-lymphocyte ratio, NLR. Both elevated CA19-9 and elevated NLR were associated with poorer survival. Further, treatment with ABRAXANE plus gemcitabine appeared to reduce the effect of CA19-9 as a poor prognostic factor, as similar overall survival was observed regardless of CA19-9 level.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
20:10 EDTCELGCelgene says patent challenges are baseless, Reuters reports
Subscribe for More Information
July 28, 2015
07:31 EDTCELGCelgene commences tender offer for Receptos
Subscribe for More Information
July 27, 2015
10:40 EDTCELGIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
08:38 EDTCELGAnalysts divided on Biogen following $85 selloff
Subscribe for More Information
July 24, 2015
08:08 EDTCELGCelgene price target raised to $190 from $156 at Canaccord
Subscribe for More Information
July 23, 2015
19:50 EDTCELGCelgene price target raised to $163 from $146 at Cantor
Subscribe for More Information
10:50 EDTCELGCelgene positioned for sustainable growth, says Piper Jaffray
Subscribe for More Information
07:37 EDTCELGCelgene reports Q2 Revlimid sales up 19% to $1.44B
ABRAXANE« sales for the second quarter were $244 million, a 13 percent increase. POMALYST«/IMNOVID« sales for the second quarter were $235 million, an increase of 46%. VIDAZA« sales in the second quarter remained flat year-over-year at $152 million. OTEZLA« sales for the second quarter were $90 million, increasing 49 percent over the first quarter of 2015.
07:37 EDTCELGCelgene raises FY15 adjusted EPS view to $4.75-$4.85 from $4.60-$4.75
Subscribe for More Information
07:32 EDTCELGCelgene reports Q2 adjusted EPS $1.23, consensus $1.20
Subscribe for More Information
July 22, 2015
15:26 EDTCELGNotable companies reporting before tomorrow's open
Subscribe for More Information
09:28 EDTCELGBiogen downgraded to Neutral at Piper Jaffray after Alzheimer's data
Subscribe for More Information
July 21, 2015
11:03 EDTCELGCelgene treatment of pediatric Crohn's disease receives FDA orphan designation
Subscribe for More Information
06:29 EDTCELGCelgene price target raised to $160 from $147 at Piper Jaffray
Subscribe for More Information
06:24 EDTCELGPiper expects 'stronger, bolder' move from Biogen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use